Management of cutaneous dermatomyositis
Identifieur interne : 001379 ( Main/Exploration ); précédent : 001378; suivant : 001380Management of cutaneous dermatomyositis
Auteurs : Christina Lam [États-Unis, Canada] ; Ruth Ann Vleugels [États-Unis]Source :
- Dermatologic Therapy [ 1396-0296 ] ; 2012-03.
English descriptors
- Teeft :
- Acad, Acad dermatol, Amyopathic, Amyopathic dermatomyositis, Antimalarial, Antipruritic, Arch dermatol, Arthritis rheum, Autoimmune, Azathioprine, Cadm, Calcineurin, Calcinosis, Calcinosis cutis, Calcinosis universalis, Callen, Case report, Case reports, Case series, Cell transplantation, Clin, Clin rheumatol, Cnis, Comorbidities, Complete resolution, Corticosteroid, Cutaneous, Cutaneous dermatomyositis, Cutaneous disease, Cutaneous lesions, Cutaneous lupus, Cutaneous manifestations, Cutis, Cyclophosphamide, Cyclosporin, Cyclosporine, Dapsone, Dermatitis, Dermatol, Dermatology, Dermatomyositis, Dos, Erythema, Erythematosus, Etanercept, Hydroxychloroquine, Idiopathic, Idiopathic myopathies, Immunoglobulin, Infusion, Intravenous, Intravenous immunoglobulin, Intravenous immunoglobulin therapy, Ivig, Juvenile dermatomyositis, Lesion, Lupus, Malignancy, Medication, Methotrexate, Methylprednisolone, Mofetil, Muscle disease, Muscle weakness, Mycophenolate, Mycophenolate mofetil, Myopathy, Myositis, Ndings, Neurol, Open study, Pediatric, Pediatric patients, Photoprotection, Polymyositis, Pruritus, Randomized, Refractory, Refractory cutaneous, Retrospective, Retrospective study, Rheum, Rheumatoid arthritis, Rheumatol, Rheumatology, Rituximab, Side effects, Skin disease, Skin lesions, Sontheimer, Steroid, Subcutaneous, Successful treatment, Systemic, Systemic corticosteroids, Tacrolimus, Toxicity, Transplantation, Universalis, Vleugels.
Abstract
Dermatomyositis (DM) is traditionally classified as an idiopathic inflammatory myopathy distinguished by muscle weakness and characteristic cutaneous findings. Patients presenting with the skin manifestations in the absence of clinical evidence of muscle weakness are categorized as clinically amyopathic DM. The symptoms associated with the cutaneous findings can be particularly debilitating, and a discordant response to therapy exists between muscle and skin disease. Various therapeutic agents and treatment approaches have been described, both for the cutaneous and extracutaneous manifestations; however, a paucity of controlled studies in this disease leads to limitations in interpreting the available data. In this review, emphasis is placed specifically on summarizing the current literature regarding management of cutaneous DM. In addition, an algorithmic approach to treatment of skin disease is presented.
Url:
DOI: 10.1111/j.1529-8019.2012.01491.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000390
- to stream Istex, to step Curation: 000390
- to stream Istex, to step Checkpoint: 000388
- to stream Main, to step Merge: 001380
- to stream Main, to step Curation: 001379
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Management of cutaneous dermatomyositis</title><author><name sortKey="Lam, Christina" sort="Lam, Christina" uniqKey="Lam C" first="Christina" last="Lam">Christina Lam</name></author><author><name sortKey="Vleugels, Ruth Ann" sort="Vleugels, Ruth Ann" uniqKey="Vleugels R" first="Ruth Ann" last="Vleugels">Ruth Ann Vleugels</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F2D22B15210E06F4F86113EECB18B603F49B177B</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1111/j.1529-8019.2012.01491.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-KKQZXZVX-K/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000390</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000390</idno><idno type="wicri:Area/Istex/Curation">000390</idno><idno type="wicri:Area/Istex/Checkpoint">000388</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000388</idno><idno type="wicri:doubleKey">1396-0296:2012:Lam C:management:of:cutaneous</idno><idno type="wicri:Area/Main/Merge">001380</idno><idno type="wicri:Area/Main/Curation">001379</idno><idno type="wicri:Area/Main/Exploration">001379</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Management of cutaneous dermatomyositis</title><author><name sortKey="Lam, Christina" sort="Lam, Christina" uniqKey="Lam C" first="Christina" last="Lam">Christina Lam</name><affiliation wicri:level="3"><country>États-Unis</country><placeName><settlement type="city">Boston</settlement><region type="state">Massachusetts</region></placeName><wicri:orgArea>Department of Dermatology, Brigham and Women's Hospital, Massachusetts</wicri:orgArea></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Canada</country></affiliation></author><author><name sortKey="Vleugels, Ruth Ann" sort="Vleugels, Ruth Ann" uniqKey="Vleugels R" first="Ruth Ann" last="Vleugels">Ruth Ann Vleugels</name><affiliation wicri:level="3"><country>États-Unis</country><placeName><settlement type="city">Boston</settlement><region type="state">Massachusetts</region></placeName><wicri:orgArea>Department of Dermatology, Brigham and Women's Hospital, Massachusetts</wicri:orgArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Dermatologic Therapy</title><title level="j" type="sub">Management of collagen vascular disease and related disorders</title><title level="j" type="alt">DERMATOLOGIC THERAPY</title><idno type="ISSN">1396-0296</idno><idno type="eISSN">1529-8019</idno><imprint><biblScope unit="vol">25</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="112">112</biblScope><biblScope unit="page" to="134">134</biblScope><biblScope unit="page-count">23</biblScope><date type="published" when="2012-03">2012-03</date></imprint><idno type="ISSN">1396-0296</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1396-0296</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acad</term><term>Acad dermatol</term><term>Amyopathic</term><term>Amyopathic dermatomyositis</term><term>Antimalarial</term><term>Antipruritic</term><term>Arch dermatol</term><term>Arthritis rheum</term><term>Autoimmune</term><term>Azathioprine</term><term>Cadm</term><term>Calcineurin</term><term>Calcinosis</term><term>Calcinosis cutis</term><term>Calcinosis universalis</term><term>Callen</term><term>Case report</term><term>Case reports</term><term>Case series</term><term>Cell transplantation</term><term>Clin</term><term>Clin rheumatol</term><term>Cnis</term><term>Comorbidities</term><term>Complete resolution</term><term>Corticosteroid</term><term>Cutaneous</term><term>Cutaneous dermatomyositis</term><term>Cutaneous disease</term><term>Cutaneous lesions</term><term>Cutaneous lupus</term><term>Cutaneous manifestations</term><term>Cutis</term><term>Cyclophosphamide</term><term>Cyclosporin</term><term>Cyclosporine</term><term>Dapsone</term><term>Dermatitis</term><term>Dermatol</term><term>Dermatology</term><term>Dermatomyositis</term><term>Dos</term><term>Erythema</term><term>Erythematosus</term><term>Etanercept</term><term>Hydroxychloroquine</term><term>Idiopathic</term><term>Idiopathic myopathies</term><term>Immunoglobulin</term><term>Infusion</term><term>Intravenous</term><term>Intravenous immunoglobulin</term><term>Intravenous immunoglobulin therapy</term><term>Ivig</term><term>Juvenile dermatomyositis</term><term>Lesion</term><term>Lupus</term><term>Malignancy</term><term>Medication</term><term>Methotrexate</term><term>Methylprednisolone</term><term>Mofetil</term><term>Muscle disease</term><term>Muscle weakness</term><term>Mycophenolate</term><term>Mycophenolate mofetil</term><term>Myopathy</term><term>Myositis</term><term>Ndings</term><term>Neurol</term><term>Open study</term><term>Pediatric</term><term>Pediatric patients</term><term>Photoprotection</term><term>Polymyositis</term><term>Pruritus</term><term>Randomized</term><term>Refractory</term><term>Refractory cutaneous</term><term>Retrospective</term><term>Retrospective study</term><term>Rheum</term><term>Rheumatoid arthritis</term><term>Rheumatol</term><term>Rheumatology</term><term>Rituximab</term><term>Side effects</term><term>Skin disease</term><term>Skin lesions</term><term>Sontheimer</term><term>Steroid</term><term>Subcutaneous</term><term>Successful treatment</term><term>Systemic</term><term>Systemic corticosteroids</term><term>Tacrolimus</term><term>Toxicity</term><term>Transplantation</term><term>Universalis</term><term>Vleugels</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">Dermatomyositis (DM) is traditionally classified as an idiopathic inflammatory myopathy distinguished by muscle weakness and characteristic cutaneous findings. Patients presenting with the skin manifestations in the absence of clinical evidence of muscle weakness are categorized as clinically amyopathic DM. The symptoms associated with the cutaneous findings can be particularly debilitating, and a discordant response to therapy exists between muscle and skin disease. Various therapeutic agents and treatment approaches have been described, both for the cutaneous and extracutaneous manifestations; however, a paucity of controlled studies in this disease leads to limitations in interpreting the available data. In this review, emphasis is placed specifically on summarizing the current literature regarding management of cutaneous DM. In addition, an algorithmic approach to treatment of skin disease is presented.</div></front></TEI><affiliations><list><country><li>Canada</li><li>États-Unis</li></country><region><li>Massachusetts</li></region><settlement><li>Boston</li></settlement></list><tree><country name="États-Unis"><region name="Massachusetts"><name sortKey="Lam, Christina" sort="Lam, Christina" uniqKey="Lam C" first="Christina" last="Lam">Christina Lam</name></region><name sortKey="Vleugels, Ruth Ann" sort="Vleugels, Ruth Ann" uniqKey="Vleugels R" first="Ruth Ann" last="Vleugels">Ruth Ann Vleugels</name></country><country name="Canada"><noRegion><name sortKey="Lam, Christina" sort="Lam, Christina" uniqKey="Lam C" first="Christina" last="Lam">Christina Lam</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001379 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001379 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:F2D22B15210E06F4F86113EECB18B603F49B177B
|texte= Management of cutaneous dermatomyositis
}}
| This area was generated with Dilib version V0.6.33. |  |